SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-045797
Filing Date
2023-08-31
Accepted
2023-08-31 16:17:18
Documents
14
Period of Report
2023-08-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atai-20230825.htm   iXBRL 8-K 76350
2 EX-10.1 atai-ex10_1.htm EX-10.1 198845
  Complete submission text file 0000950170-23-045797.txt   466223

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atai-20230825_pre.xml EX-101.PRE 15042
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atai-20230825_def.xml EX-101.DEF 14842
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atai-20230825_lab.xml EX-101.LAB 24178
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atai-20230825.xsd EX-101.SCH 3923
8 EXTRACTED XBRL INSTANCE DOCUMENT atai-20230825_htm.xml XML 4693
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 231229249
SIC: 2834 Pharmaceutical Preparations